By analyzing the number of CTC in blood samples from 32 patients with different tumors collected in each group, and comparing the sensitivity of different CTC separation schemes with different tumor-markers, it’s shown in this study that single use of EpCAM, EGFR, Her-2 and MUC-1 could realize a higher CTC separation positive rate than that of combination use. The gene discussed is MUC1; the disease is neoplasm.